Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10144371 | 0.84 | DPP4 (0.34) | DPP4 | |
| SCHEMBL10144301 | 0.77 | SMN1; SMN2 (0.34) | SMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL10121065 | 0.71 | — | — | |
| SCHEMBL29818831 | 0.70 | CTSL (0.36) | ASGR1 | |
| SCHEMBL10120885 | 0.67 | CTSD (0.30) | — | |
| SCHEMBL13255730 | 0.66 | SPHK1 (0.38) | SMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL10144487 | 0.65 | SPHK1 (0.39) | — | |
| SCHEMBL17695815 | 0.64 | SMN1; SMN2 (0.49) | SMN1; SMN2ALDH1A1TDP1ASGR1 | |
| SCHEMBL14755323 | 0.64 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL10120950 | 0.64 | ASGR1 (0.34) | ASGR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022045-A1 | BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS | VENKATRAMAN SHANKAR (US) | 2012-01-26 | — | — | US | disclosed |
| WO-2010088167-A1 | BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022045-A1 | BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS | CCND3, CDK3, CDK2 | SMN1; SMN2 3919/4885ALDH1A1 2994/4885TDP1 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.